Arbutus Biopharma Logo
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
26 mars 2020 16h05 HE | Arbutus Biopharma Corporation
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional...
Arbutus Biopharma Logo
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
05 mars 2020 07h30 HE | Arbutus Biopharma Corporation
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic...
Arbutus Biopharma Logo
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
27 févr. 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Biopharma Logo
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
10 févr. 2020 08h00 HE | Arbutus Biopharma Corporation
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
06 nov. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2019 Financial Results
30 oct. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Biopharma Logo
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
03 oct. 2019 16h05 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue...
Arbutus Biopharma Logo
Arbutus to Participate in Upcoming Investor Conferences
26 sept. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the...
Arbutus Biopharma Logo
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
20 août 2019 16h05 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that...
Arbutus Biopharma Logo
Arbutus to Participate at Wedbush PacGrow Healthcare Conference
06 août 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....